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Abstract
Background: Cisplatin, a chemotherapy used to treat solid tumors, causes acute kidney injury (AKI), a known risk factor
for chronic kidney disease and mortality. AKI diagnosis relies on biomarkers which are only measurable after kidney damage
has occurred and functional impairment is apparent; this prevents timely AKI diagnosis and treatment. Metabolomics seeks
to identify metabolite patterns involved in cell tissue metabolism related to disease or patient factors. The A Canadian study
of Cisplatin mEtabolomics and NephroToxicity (ACCENT) team was established to harness the power of metabolomics to
identify novel biomarkers that predict risk and discriminate for presence of cisplatin nephrotoxicity, so that early intervention
strategies to mitigate onset and severity of AKI can be implemented.
Objective: Describe the design and methods of the ACCENT study which aims to identify and validate metabolomic
profiles in urine and serum associated with risk for cisplatin-mediated nephrotoxicity in children and adults.
Design: Observational prospective cohort study.
Setting: Six Canadian oncology centers (3 pediatric, 1 adult and 2 both).
Patients: Three hundred adults and 300 children planned to receive cisplatin therapy.
Measurements: During two cisplatin infusion cycles, serum and urine will be measured for creatinine and electrolytes
to ascertain AKI. Many patient and disease variables will be collected prospectively at baseline and throughout therapy.
Metabolomic analyses of serum and urine will be done using mass spectrometry. An untargeted metabolomics approach will
be used to analyze serum and urine samples before and after cisplatin infusions to identify candidate biomarkers of cisplatin
AKI. Candidate metabolites will be validated using an independent cohort.
Methods: Patients will be recruited before their first cycle of cisplatin. Blood and urine will be collected at specified time
points before and after cisplatin during the first infusion and an infusion later during cancer treatment. The primary outcome
is AKI, defined using a traditional serum creatinine-based definition and an electrolyte abnormality-based definition. Chart
review 3 months after cisplatin therapy end will be conducted to document kidney health and survival.
Limitations: It may not be possible to adjust for all measured and unmeasured confounders when evaluating prediction of
AKI using metabolite profiles. Collection of data across multiple sites will be a challenge.
Conclusions: ACCENT is the largest study of children and adults treated with cisplatin and aims to reimagine the current
model for AKI diagnoses using metabolomics. The identification of biomarkers predicting and detecting AKI in children and
adults treated with cisplatin can greatly inform future clinical investigations and practices.
Abrégé
Contexte: Le cisplatine, un agent utilisé en chimiothérapie pour traiter les tumeurs solides, entraîne de l’insuffisance
rénale aiguë (IRA); un facteur de risque connu de néphropathie chronique et de mortalité. Le diagnostic de l’IRA repose
sur des biomarqueurs qui ne sont mesurables qu’après l’apparition d’une lésion rénale et d’une déficience fonctionnelle;
ce qui empêche le diagnostic et le traitement précoce de la maladie. La métabolomique s’efforce d’établir le profil des
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons AttributionNonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and
distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages
(https://us.sagepub.com/en-us/nam/open-access-at-sage).
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métabolites impliqués dans le métabolisme des tissus cellulaires en relation avec des facteurs liés à la maladie ou au patient.
Une étude canadienne portant sur la métabolomique et la néphrotoxicité du cisplatine (ACCENT) s’est amorcée, elle
explore la puissance de la métabolomique dans l’identification de nouveaux biomarqueurs permettant de prédire le risque de
néphrotoxicité du cisplatine et d’en distinguer la présence. L’objectif étant de mettre en œuvre des stratégies d’intervention
précoce, dès l’apparition de l’IRA, et de limiter la gravité de la maladie.
Objectifs: Décrire la conception et la méthodologie de l’étude ACCENT. Cette étude vise à établir et à valider des profils
métabolomiques, dans l’urine et le sérum, associés au risque de néphrotoxicité médiée par le cisplatine chez les enfants et
les adultes.
Type d’étude: Étude de cohorte prospective.
Cadre: Six centres canadiens d’oncologie (trois centres pédiatriques, un centre pour adultes et deux centres mixtes).
Sujets : L’étude porte sur 300 adultes et 300 enfants pour qui un traitement par cisplatine est prévu.
Mesures: L’IRA sera confirmée par mesure de la créatinine et des électrolytes dans le sérum et l’urine au cours de deux cycles
de perfusion de cisplatine. De nombreuses variables relatives au patient et à la maladie seront recueillies prospectivement
avant et pendant le traitement. Les analyses métabolomiques des échantillons de sérum et d’urine seront effectuées par
spectrométrie de masse. Une approche métabolomique non ciblée sera utilisée pour analyser les échantillons avant et après
les perfusions de cisplatine pour identifier les biomarqueurs candidats d’une IRA découlant du traitement par cisplatine. Les
métabolites candidats seront validés dans une cohorte indépendante.
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Méthodologie: Les patients seront recrutés avant le premier cycle de cisplatine. Le sang et l’urine seront recueillis à des
moments précis, soit avant et pendant le traitement; plus précisément lors de la première perfusion, puis d’une perfusion
subséquente au cours du traitement contre le cancer. Le principal critère d’évaluation est la présence d’IRA, laquelle sera
établie selon la définition classique fondée sur la mesure de la créatinine sérique et d’une autre définition fondée sur les
anomalies électrolytiques. Un examen des dossiers trois mois après la fin du traitement par cisplatine sera effectué afin de
documenter la santé rénale et la survie des patients.
Limites: Il pourrait être impossible de corriger tous les facteurs confusionnels mesurés et non mesurés lors de l’évaluation
de la prédiction de l’IRA à l’aide de profils de métabolites. La collecte de données sur plusieurs sites sera un défi.
Conclusion: ACCENT est la plus vaste étude portant sur des enfants et des adultes traités avec le cisplatine; cette étude
tente de revoir le modèle actuel en utilisant la métabolomique pour diagnostiquer l’IRA. L’identification de biomarqueurs
permettant de prédire et de détecter l’IRA chez les enfants et les adultes traités par cisplatine pourrait grandement éclairer
les futures études et pratiques cliniques.
Renseignements sur l’enregistrement de l’essai clinique: ClinicalTrials.gov, insuffisance rénale induite par le cisplatine,
NCT04442516
Keywords
acute kidney injury, metabolomics, cisplatin nephrotoxicity, pediatrics, cohort study
Received June 17, 2021. Accepted for publication September 18, 2021.

Introduction
Cisplatin is a commonly used chemotherapeutic agent for
multiple adult and pediatric cancers.1 One of the most common adverse effects of cisplatin is nephrotoxicity.2,3 Acute
kidney injury (AKI) occurs in up to 30% of children and 33%
of adults treated with cisplatin.4,5AKI is an established risk
factor for short- and long-term morbidity, chronic kidney
disease (CKD), cardiovascular disease, and mortality in
adults.6-14 In the Applying Biomarkers to Minimize LongTerm Effects of Childhood/Adolescent Cancer Treatment
(ABLE) Nephrotoxicity Study, a national cohort of children
treated with cisplatin (n = 159), 40% showed signs of CKD
at 12-months post cisplatin therapy (unpublished data).15
CKD is an established potent cardiovascular risk factor.
A challenge in detecting nephrotoxicity is the suboptimal
performance of current diagnostic methods. Currently, the
clinical diagnosis of AKI is based on acute serum creatinine
(SCr) rise and decreased urine output—biomarkers only evident after kidney damage has progressed to functional
impairment whereupon mitigation strategies are ineffective.16 Biomarkers that can predict cisplatin nephrotoxicity
risk or diagnose nephrotoxicity early may substantially
increase the opportunity for early intervention, which might
mitigate AKI severity and its long-term effects.
Metabolomics seeks to identify metabolite patterns
involved in cell or tissue metabolism related to disease or
patient factors like lifestyle and genetics. Unlike proteomics,
metabolomics represents the end-products of processes occurring due to alterations of the genome and proteome. Serum
and urine are ideal for sampling the metabolome and can
reveal disease-related changes earlier than existing diagnostic
methods.17 As cancer survival improves, chemotherapy-associated morbidity prevention is important to improve quality of
life in survivors. For cisplatin, tests that could predict AKI risk

or diagnose AKI before significant functional loss may afford
opportunities for prevention or early intervention including
individualized dosing protocols to mitigate cisplatin
nephrotoxicity.18
We describe the design and methods of ACCENT (A
Canadian study of Cisplatin mEtabolomics and
NephroToxicity), a multidisciplinary, prospective observational cohort study using metabolomics to identify urine and
serum metabolite profiles that could predict the risk for cisplatin-induced AKI and identify early-stage cisplatin-mediated
nephrotoxicity in children and adults treated for cancer.

Study Team and Infrastructure
ACCENT is a Canada-wide, multicenter study leveraging a
network of experts (Nominated Principal Applicant is Dr Brad
Urquhart [clinical pharmacologist, University of Western
Ontario (UWO)]; co-Principal Applicants are Dr Michael
Zappitelli and Dr Tom Blydt-Hansen [pediatric nephrologists,
University of Toronto and University of British Columbia,
respectively]). Three core groups led by the principal investigators will oversee (1) metabolomics analysis, (2) data/biorepository & central study coordination, and (3) data & statistical
analysis. The main coordinating center is at The Hospital for
Sick Children (SickKids) in Toronto, ON, Canada where the
database and study specimens will be housed. The organization of collaborators, their roles, and site investigators are
shown in Figure 1. Principal investigators and their study
coordinators meet biweekly to discuss study roadmap, track
progress, and troubleshoot.

Rationale
Cisplatin-mediated kidney tubule injury often causes AKI,
characterized by decreased glomerular filtration rate (GFR),
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Figure 1. Steering committee, participating centers, and collaborators.

Note. The figure demonstrates the individuals involved in each section of the project and their locations. UBC, University of British Columbia; UWO,
University of Western Ontario; UofA, University of Alberta; UofM, University of Manitoba; PMH, Princess Margaret Hospital; BU, Boston University. This
figure was created with BioRender.com.

hypertension, and sometimes need for dialysis. Proximal
tubule injury from cisplatin also manifests as polyuria and
electrolyte wasting (potassium, magnesium, phosphate).3,19-21
Although higher dose, very young age, and female sex are
known risk factors for cisplatin-mediated tubule injury, accurate prediction of patients who will develop nephrotoxicity
remains elusive.22-24
Cisplatin AKI mechanisms. The majority of cisplatin is eliminated by the kidneys. Proximal tubule cells are a major site
of cisplatin accumulation and injury, mediated by several
transport proteins (Figure 2).25,26 Organic cation transporter 2
(OCT2) and copper transporter 1 (CTR1) on the basolateral
membrane mediate cisplatin uptake from blood into proximal tubule cells.27-30 Cisplatin is metabolized to reactive thiol
metabolites [GSH-Pt, Cys-Gly-Pt, NAC-1] which are substrates of organic anion transporters (OAT1 and OAT3).25,31,32
Cisplatin and its metabolites induce necrosis of proximal
tubule cells by causing pro-inflammatory cytokine release,
endoplasmic reticulum stress, mitochondrial damage, and
generation of reactive oxygen species.33
In addition, the multidrug and toxin extrusion protein
(MATE1) and multidrug resistance associated protein
(MRP2) mediate efflux of cisplatin and its metabolites into
the tubule lumen.26,34 Modulation of these transporters plays

Figure 2. Schematic of proposed proximal tubule cisplatin
toxicity.

Note. GST = glutathione S-transferase; GGT = γ glutamyl transpeptidase;
APN = aminopeptidase.24,25,27,33 This figure was created with BioRender.
com.

a critical role in cisplatin AKI, by determining tubule exposure to cisplatin. These transporters have endogenous small
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Table 1. Cisplatin AKI Prevalence and Timing During Cisplatin Treatment in the ABLE Cohort.
n with AKI (%)
AKI definition
KDIGO (SCr)
NCI (electrolyte)
Both KDIGO and NCI

Early CisP cycle

Later CisP cycle

Early or later

48 (30%)
106 (67%)
32 (20%)

23 (16%)
100 (70%)
16 (11%)

59 (37%)
134 (84%)
41 (26%)

Post-CisP day of AKI
KDIGO (SCr)
NCI (electrolyte)

Early & later
12 (8%)
72 (143%)
7 (5%)

Median (minimum, maximum)
2 (1 to 5)
1.5 (1 to 3)

2 (1 to 4)
1 (1 to 2)

Note. ABLE study (159 children). Kidney Disease: Improving Global Outcomes (KDIGO): SCr-definition; National Cancer Institute (NCI): electrolytebased definition. AKI = acute kidney injury; ABLE = Applying Biomarkers to Minimize Long-Term Effects; SCr = serum creatinine.

molecule substrates whose concentrations can impact cisplatin transport and toxicity. For example, the metabolite trimethylamine N-oxide (TMAO) is a substrate of OCT2, while
indoxyl sulfate, p-cresyl sulfate, phenyl sulfate, and hippuric
acid are OAT transporter substrates.35-39 In animal models,
cisplatin AKI can be detected based on altered urinary
TMAO, indoxyl sulfate, and hippuric acid concentrations.24,40-45 Interindividual variability in cisplatin transporter
activity may underlie toxicity and can be characterized by
examining serum and urine metabolite patterns of transporter
substrates. Interindividual differences in levels of metabolites that are substrates for cisplatin transporters may help
identify individualized risk of cisplatin AKI.46-50
Proximal tubule mitochondria are a primary target of cisplatin nephrotoxicity and cisplatin has been shown to alter
metabolites associated with oxidant stress (eg, glutathione)
and mitochondrial dysfunction (eg, fatty acids) in response
to injury.51,52 Metabolites associated with oxidant stress or
mitochondrial dysfunction may be metabolic markers of
early nephrotoxicity.
Need for predictive cisplatin AKI biomarkers. In ABLE, onset
of AKI with elevated SCr occurred in children within 3 days
following cisplatin infusion (Table 1), consistent with timing
of AKI evolution in other injury settings.15,16 By this time,
intervention to mitigate SCr rise due to tubule injury, the
most common reason for clinically significant AKI, is limited to supportive care, due to established tissue damage and
impaired kidney function.16,53
There is international consensus that earlier, more specific
AKI diagnosis is needed to identify early harm mitigating
treatments (eg, conservative treatments including altering
cisplatin dosing or timing, active nephrotoxic medication
avoidance, or hydration protocols; experimental treatments
including pharmacotherapy from animal studies described in
the references).16,18,30,54-62 Cisplatin injury occurs through a
known mechanism, providing a unique opportunity to identify predictive markers. Although cisplatin nephrotoxicity
has not been studied using metabolomic techniques in

humans, pre-clinical studies identified metabolites that were
detectable before SCr rise (Table 2).41
Metabolomic approaches have been applied in humans to
determine pretreatment risk of drug toxicity for other chemotherapies like capecitabine and improved prediction of drug
efficacy or toxicity in several other diseases.64 Likewise,
ACCENT is designed to identify metabolites involved in cisplatin AKI that allow diagnosis before SCr rise.

Methods
ACCENT Hypotheses and Study Aims
Hypothesis 1: Urine and serum metabolite profiles will be
identified that predict the risk of cisplatin AKI.
Hypothesis 2: Urine and serum metabolite profiles will be
identified, including markers of oxidant stress and mitochondrial dysfunction that diagnose cisplatin AKI prior to
the reference standard clinical evidence of AKI (SCr rise
and/or electrolyte abnormalities).
To address the two hypotheses, the following aims will be
completed:
1.

2.

Identify patterns of metabolites and specific metabolites prior to and shortly after cisplatin treatment that
predict AKI risk and identify the onset of AKI early
(discovery cohort).
To independently validate the findings and develop a
precision medicine algorithm using metabolites to
predict patients at high risk for developing cisplatin
AKI (validation cohort).

Study Design and Setting
This is a prospective, multicenter, observational cohort study in
300 adults and 300 children treated with cisplatin. This study
includes 6 centers (3 pediatric; 2 combined pediatric and adult;
1 adult). Each participating center is led by the site investigator,
a clinician supervising study recruitment (Table 3).
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Table 2. Non-Exhaustive Summary of Known Metabolites Related to Cisplatin Nephrotoxicity.
Target

Metabolite

Pathophysiology

OCT2

TMAO, dopamine,
tryptophan

OAT1, OAT3

Uraemic toxins: hippuric
acid, indoxyl sulfate

p-cresyl sulfate (PCS)

kynurenine, pantothenic
acid, cyclic nucleotides,
phenyl sulfate

MATE1, MRP2

glutathione, bilirubin

Amino acid
transport

alanine, valine, leucine,
methionine

Study design
30,63

OCT2 is involved in cisplatin uptake.
Metabolites found to be upregulated with
nephrotoxicity.24,39,40
OAT-1/OAT3 is responsible for the
cellular uptake of these organic anions
which have been shown to concentration
dependently stimulate cellular free radical
production.35–37
The serum levels of PCS are ~30 times
higher than in healthy subjects as renal
dysfunction progresses, OAT1/OAT3 are
involved in the uptake of PCS.38
OAT1 mediates transport of these
metabolites which are toxins associated
with renal failure and uremia.36

Transgenic expression of human MRP2
gene in knockout mice reduces cisplatin
accumulation. Kidneys from naive Mrp2null mice had elevated glutathione
S-transferase mRNA levels, which could
increase the formation of cisplatinglutathione conjugates that may be
metabolized to toxic thiol intermediates.26
Metabolites found on analysis of urine
after cisplatin induced acute renal failure.
Aminoaciduria may be explained by
the effects of cisplatin on amino acid
transporters.41

Transporter knockout mice study.
Renal proximal tubular cell line,
opossum kidney (OK) cells, was
transformed with human OAT1.
Analyzed uptake of organic anions in
transformed cells.37
Uptake of PCS was investigated using
rat renal cortical slices and human
proximal tubular cells.38
Untargeted metabolomics on the plasma
and urine from OAT1 knockout
mice used to identify metabolites. A
pharmacophore model based on several
identified Oat1 substrates was used to
screen the National Cancer Institute
database and candidate compounds
interacting with Oat1 were validated in
an in vitro assay.36
Transgenic expression of Mrptransporter in MRP2 null mice.

Metabolomic study of cisplatin-induced
nephrotoxicity.

Note. Experiments conducted with animal models..

Table 3. Participating Sites of the Cisplatin Metabolomics Study.
Participating site (hospital)
Pediatric cohort (N = 141 over 3 years)
Hospital for Sick Children
McGill University
University of British Columbia
University of Manitoba
University of Western Ontario
Adult cohort (N = 300 over 2 years)
Princess Margaret
University of British Columbia
University of Western Ontario

Site investigator

Site coordinator

Dr Michael Zappitelli/Dr Paul Nathan
Dr Sharon Abish
Dr Tom Blydt-Hansen/Dr Rod Rassekh
Dr Geoffrey Cuvelier
Dr Alexandra Zorzi
Dr Geoff Liu
Dr Cheryl Ho
Dr Sara Kuruvilla Dr Eric Winquist Dr
Stephen Welch

Site coordinators will conduct study visits and be trained via
teleconference by the main coordinating center before initiating study activities.

City

Grace Tran
Dominique Lafreniere
Ritu Ratan
Krista Meuller
Rebekah Hiebert
Barbara Murray Awatif Abuzgaia

Toronto
Montreal
Vancouver
Winnipeg
London

Devalben Patel Khaleeq Khan
Aria Shokoohi
Kathie Baer Robin Sachdeva

Toronto
Vancouver
London

Following patient recruitment, untargeted metabolomics
using liquid chromatography mass spectrometry (LC-MS)
will be performed on serum and urine from 200 adults and
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Table 4. Inclusion and Exclusion Criteria for Nephrotoxic Medications.
Child cohort

Adult cohort

• Greater than 3 months of age
• 18 years of age or older
• Less than 18 years of age
• Initiating cisplatin treatment (≥70 mg/m2) for
head/neck or lung cancers at one of the adult
• Initiating cisplatin treatment at pediatric
participating sites
participating sites.
• Consent/assent to participate in the study
Exclusion criteria
• Baseline diagnosis of CKD
• Previous use of nephrotoxic medications in the 2 weeks leading up to cisplatin treatment (see “Prohibited
Nephrotoxic Medications List”)
• Previous use of cisplatin
• Radiotherapy (total body irradiation or abdominal radiation only) in the 1 month prior to the study
• Previous hematopoietic stem cell transplant
• Any chronic or acute health condition that the investigator feels would render the patient inappropriate for
this study, including but not limited to significant uncontrolled cardiorespiratory, hepatic, infectious, or renal
disease at the discretion of the investigator
Prohibited Nephrotoxic Medications List:
• Acyclovir
• Aminoglycosides (including gentamycin, tobramycin, and amikacin)
  ○ Not inhaled tobramycin, no creams or ointments
• Amphotericin B
• Caspofungin
• Carboplatin
• Cidofovir
• Previous Cisplatin
• Cyclophosphamide
• Cyclosporine
• Nonsteroidal anti-inflammatory drugs (NSAIDs)
• Ifosfamide
• Methotrexate
• Trimethoprim
• Tacrolimus
• Vancomycin

Inclusion criteria

Note. CKD = chronic kidney disease.

200 children to identify metabolite profiles associated with
prediction or early detection of cisplatin AKI (discovery
cohort). Based on the identified metabolites, a targeted fully
quantitative, LC-MS metabolomic analysis of serum and
urine for the remaining 100 adults and 100 children will follow for independent validation (validation cohort).
AKI definition. AKI will be primarily defined by the Kidney
Disease: Improving Global Outcomes (KDIGO) definition:
SCr rise by ≥26.5 μmol/L (0.3 mg/dL) within 48 hours or to
≥1.5 times baseline, or oliguria.54 However, this definition,
developed for critical care patients, does not consider specific features of cisplatin AKI including electrolyte wasting.
The two AKI phenotypes (SCr rise, electrolyte disturbance)
may represent different injury types; a recent review concluded that the cisplatin AKI definition should include electrolyte criteria.15 The National Cancer Institute (NCI) has
published an electrolyte disturbance definition based on
which we propose a new definition of AKI which comprises
electrolyte disturbances.65 Therefore, we will classify cisplatin AKI by

a. KDIGO definition (SCr-based, primary),
b. Modified NCI electrolyte disturbance definition (electrolyte-based, ≥Grade 1 NCI-AKI, defined as Mg2+,
PO43- or K+ below age-appropriate values), or
c. Both SCr and electrolyte criteria.

Study Participants and Recruitment
Children and adults will be recruited to address known differences in drug response with age.66 Previous regular use of
any nephrotoxic medications included on the provided
“Prohibited Nephrotoxic Medications List” in the 2 weeks
prior to first cycle of cisplatin treatment will render them
ineligible to participate. These medications and other inclusion and exclusion criteria are outlined in Table 4. The
screening log describing our patient selection approach is
shown in Appendix. To minimize effects of instrument drift
and other confounders, all 600 patients will be recruited, and
AKI phenotype determined before metabolomics analysis.
After AKI classification, participants will be randomly split
into discovery and validation cohorts for analysis.
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Figure 3. Overview of experimental design.

Note. DNA is captured only once at the first cisplatin cycle. Both blood and urine are collected 6 times during the study (3 collection time points for each
of 2 cisplatin cycles).

Child cohort. ABLE was a 12-center cohort study, in which
inclusion criteria, study procedures, and data collected closely
resemble the present study. Consent was previously provided
by the 159 ABLE participants (80 males, 79 females) to use
specimens for biomarker discovery. The remaining children
will be recruited over 3 years to reach a target of 300. Collection time points for blood and urine occur during two cisplatin
infusions for both studies. However, ABLE participants could
be recruited prior to their second cisplatin cycle; in ACCENT,
only cisplatin-naive patients will be recruited. In total, 91 of
the 159 ABLE study participants were cisplatin naive.4 Five
ABLE sites will return to participate in ACCENT.
Adult cohort. A total of 300 adults will be recruited over 2 years.
A pilot and feasibility study initiated at Western University
(Urquhart) has collected data and samples on 30 patients to date.

Ethics Approval and Consent to Participate
This study is being conducted in accordance with the World
Medical Association Declaration of Helsinki. Written informed

consent (or assent) will be obtained from all participants, after
cancer diagnosis and before cisplatin treatment. Ethics approval
was granted to participating centers in one of three ways: (1)
SickKids provided overarching ethics approval for pediatric
centers (REB Number: 1000071380). Once the application was
approved at SickKids, submissions were made to ethics bodies
at other pediatric sites. (2) We took advantage of the streamlined
review process offered by the Ontario Cancer Research Ethics
Board (OCREB) for our Ontario adult sites (CTO Project ID:
3269). OCREB services Ontario hospitals/cancer centers conducting oncology trials. Upon OCREB approval, participating
centers may submit their abbreviated center-specific application
for expedited approval. (3) The British Columbia (BC) adult site
received ethics approval through their center.

Sample and Data Collection
Figure 3 summarizes the study protocol and data/biospecimen collection. The two cisplatin cycles anchoring study
procedures are the first cycle (when participants are cisplatin-naive) and a later cycle (last or second-last cycle).
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Standard clinical monitoring during cisplatin. Standard of care
assessments include serum biochemistry assays to screen for
AKI and electrolyte disturbances. Routine monitoring of
AKI, acidosis, and hypophosphatemia may sometimes
include urinary electrolyte monitoring. Other routinely performed clinical assessments include baseline assessment of
height, weight, vital signs, daily volume status, urine output,
and fluid balance. This study will record these standard of
care values.
Data will be captured in case report forms (CRFs). CRFs were
designed by the steering committee and refined following
feedback from site investigators and coordinators. Most data
described below will be obtained from retrospective and prospective chart review when feasible.
•• Baseline data includes screening/eligibility, Study ID,
sex, gender, race, date of birth, height, weight, baseline labs (SCr, eGFR), medical history, lifestyle habits, and chemotherapy treatment protocol.
•• Identical sets of data will be collected during two cisplatin cycles, including
|| Pre-Infusion: laboratory results just before cancer
therapy (electrolytes, SCr, urine analysis), administered fluids, infections leading up to treatment,
medications, blood pressure (BP), hospitalizations
|| Post-Infusion: laboratory results after cancer therapy (electrolytes, SCr, urine analysis), administered fluids, infections shortly after infusion, use
of nephrotoxic agents
•• Throughout cisplatin therapy: use of concomitant
radiotherapy, total cisplatin dose, date of cisplatin
administration, any hospital or ICU admissions, need
for dialysis, and laboratory results (monthly kidney
function and electrolytes).
•• Three-month follow-up: to record 3-month post-cancer treatment mortality and CKD status. Namely, survival status, SCr results, height, and weight for
estimating GFR, BP, electrolyte results from medical
records, urine albumin to creatinine and urine protein
to creatinine ratios and urinalysis.
Samples will be collected at study visits during 2 cisplatin infusion
cycles (Figure 3). The following will be collected:
•• Blood. Wherever possible, research blood collection
will occur simultaneous to collection for routine clinical care (children: 3 mL; adults: 10 mL).
•• Urine. An additional volume of urine (30 mL) will be
collected, from an existing urinary catheter, by midstream collection in a urine collection cup, or using
diaper- embedded cotton balls.
•• Saliva. Saliva (5 mL, in Oragene Saliva DNA kits)
will be collected once (ideally before initial cisplatin
cycle) for future genetic research. Swab will be
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accepted for those having difficulty producing
sputum.
•• Blood and urine will be collected at the following
time points; which were selected based on feasibility
discussions with each site, and a desire to have specimens from key time points useful for predicting
nephrotoxicity:
|| Before the first cisplatin dose on the same day as
the infusion (“pre”), or up to 1 week prior.
|| ~24 hours after cisplatin (“post”). This sample
should be collected as close to 24 hours following the cisplatin dose as possible and within 16-24
hours from cisplatin infusion end.
|| 4-8 days later for adults, 3-8 days later for pediatrics (“conclusion” sample).
We will use blood and urine from each time point for SCr
and electrolyte measurements to define AKI by the KDIGO
and electrolyte NCI definitions. SCr and electrolyte values
performed in routine care will also be recorded to enrich our
dataset for AKI ascertainment. If a participant is missing the
“pre” or “post” sample, no further samples will be collected
or included in the metabolomics analysis. However, baseline
and 3-month follow-up data will still be collected and compared with those included in metabolomics analysis to evaluate for bias.

Biospecimen Processing / Storage
•• Blood: centrifuged at 4°C (2000g × 10 minutes), aliquoted into 1 mL cryovials supplied in the study kits
and serum temporarily stored (up to 3 months) at
−80°C at each site.
•• Urine: poured into two 15 mL conical tubes, unprocessed and temporarily stored (up to 3 months) at
−80°C at each site.
•• Saliva: stored temporarily at room temperature at
study sites (up to 3 months).
•• 3-4 times per year, specimens will be shipped on dry
ice (DNA samples at room temperature) to the biorepository (at SickKids) where they will be stored at
−80°C until time of testing. Upon receipt of urine
specimens, urine will be thawed, centrifuged at 4°C
(2000g × 10 minutes) and aliquoted into 1 mL cryovials for storage. Samples will be stored for future
hypothesis generation and validation studies.
Data management. Once enrolled, participants will be
assigned a unique study code and entered into an online
research electronic data capture system (REDCap; a secure,
Web-based data management system housed at SickKids),
informing the main coordinating center in real-time and populating a specimen capture form. Collected samples will be
de-identified using a barcode with a unique study identification (ID) code. Bar codes will be scanned by each site into
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the REDCap database to facilitate real-time specimen tracking (collection, processing, and freezing times) by the main
coordinating center and to enable quick responses to issues.
The first online specimen log triggers electronic reminders
for future collections. This strategy, coupled with frequent
communication between the main coordinating center and
study sites, resulted in >95% sample collection success in
ABLE. Other data collected are completed on paper case
report forms (CRFs) before being scanned and uploaded to
the REDCap platform. Data will be entered by the database
manager into the central data repository with regular, integrated data checks and site queries to capture missing data
and correct errors. This will be accompanied by monthly
coordinator calls and routine engagement by the main coordinating center to address any issues. These rigorous data
quality control measures resulted in a 0.04% missing data
rate in the ABLE study. Data security and integrity are crucial, given the large clinical and metabolite data that will be
received. The database will be shared with the UBC statistical analysis core for final database management and analysis. The mass spectrometry metabolomics data from the
Urquhart lab will be encrypted and backed up daily to a
UWO network server for immediate storage, followed by
transfer/storage (with clinical data) with the support of the
High-Performance Computing for Healthcare (HPC4Health)
facility; a secure cloud providing high performance computational resources (Figure 1).

Sample Size Considerations
Metabolomics studies rarely have traditional sample size calculations because the data are highly dimensional and correlated.67 Previous studies have used synthetic data to
estimate sample sizes for metabolomics studies based on
false discovery rates (FDR).68 Assuming an FDR of 0.05,
200 metabolites, and assuming 20% of metabolites will differ between groups, around 20 subjects are required per
group.68 Based on 46% AKI incidence in the national cisplatin cohort throughout therapy, 400 subjects (200 children,
200 adults) will yield >20 subjects in each AKI phenotype
(KDIGO, NCI). The sample size determined for this study
aligns with previously published drug metabolomic studies
and cisplatin AKI incidence.69-73
Metabolomics analysis. Metabolomics analyses of serum and
urine for the discovery cohort will be done using a Waters
Xevo G2-S quadrupole time-of-flight (QToF) mass spectrometer. An untargeted metabolomics approach will be used
to analyze serum and urine samples from the discovery
cohort at the “pre” and “post” time points to identify candidate metabolite indicators of cisplatin AKI. To minimize
instrument drift, sample order will be randomized such that
“pre” and “post” samples along with the site of collection
will be injected in random order. The “pre” samples will be
used to identify biomarkers of AKI risk, and the “post”
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samples for early AKI diagnosis. Cisplatin nephrotoxicity
pathways and previous research have provided promising
candidate metabolites to consider (Table 2).24,40-43 Candidate
metabolites identified from the discovery cohort will be subjected to targeted, quantitative metabolomics on the validation cohort (both serum and urine). The fully quantitative
metabolite assays will be performed on an AB Sciex QTRAP
5500 mass spectrometer using kits developed by Dr Wishart
from The Metabolomics Innovation Centre.

Data Analysis
Discovery cohort. An overview of the data analysis process is
outlined in Figure 4. Data from untargeted metabolomics
will be processed using the isotopologue parameter optimization (IPO) and XCMS packages in R. IPO will be performed on pooled sample injections to optimize the
parameters used for XCMS-facilitated data processing (Figure 4). Serum and urine metabolite peak areas will be normalized to internal standard peak areas, with additional
normalization to creatinine in urine specimens. We will use
EZInfo 2.0 (Umetrics, Umeå, Sweden) to perform multivariate analyses. Principal component analysis (PCA) will be
used to visualize general data trends, and orthogonal partial
least squares discriminant analysis (OPLS-DA) will be used
to determine the metabolites with the greatest contribution to
the variation/separation between groups of interest (Figure
4). Variable Importance in Projection (VIP) scores will be
used to rank metabolites by their discriminating importance
and metabolites with VIP score >1 (standard for untargeted
metabolomics studies) will be identified as candidates.74-77
Candidate metabolites will be subjected to multivariate analysis to exclude possible confounding with other clinical/
patient characteristics. Subsequently, a nested case-control
approach will be used for quantitative metabolomics analysis
to measure the absolute concentration of candidate metabolites on 120 repeated samples (60 adults, 60 children) from
the discovery cohort (n = 20 no AKI, n = 20 KDIGO AKI,
n = 20 NCI AKI). Absolute quantification of candidate
metabolites is an essential step in transitioning candidate
biomarkers to robust tests that can be compared between
testing sites.78-81 PCA, OPLS-DA, and VIP ranking of the
fully quantified metabolites will be repeated to ensure the
most reliable candidate metabolites move forward to validation testing (Aim 2). We anticipate metabolite profiles for
KDIGO AKI (SCr based) vs NCI AKI (electrolyte based)
phenotypes will differ. The primary analysis will compare
KDIGO AKI vs non-AKI metabolite profiles. Secondary
analyses will compare metabolite profiles of (1) males vs
females, (2) NCI (electrolyte) AKI vs non-AKI, and (3)
KDIGO and NCI AKI vs no AKI.
Validation cohort. This analysis will use candidate metabolites
measured in the discovery cohort to validate findings. This
step allows the independent validation of the findings from the
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LC-MS and Data Processing
• Conduct metabolomics analysis using LC-MS
• Use the isotopologue parameter opmizaon (IPO) package in R with
pooled injections to optimize peak picking, retenon me correcon, and
grouping parameters for use in the XCMS package in R

LC-MS + Data
Processing

• XCMS is designed for automated processing of LC-MS metabolomics data
• Use the parameters generated by IPO for XCMS peak picking and data
processing of metabolomics run
• Normalize data to internal standards

PCA
Principal Component Analysis (PCA)
•
•
•
•
•
•

•
•
•
•
•

•
•
•
•

•
•
•
•
•

Unsupervised analysis
Each point represents a single sample
Finds directions in the multi-dimensional dataspace containing the most
variaon – these are principal components (PC)
The 1st PC (PC1) represents the direcon in the dataspace with the most
variaon, the 2nd (PC2) represents the 2nd most variaon, and so on
PCA projects data onto a 2D space using PC1 and PC2 as the axes,
maximizing variability and reducing dimensionality
Visual separation indicates metabolic differences between your groups of
interest

Orthogonal Paral Least Squares
Discriminant Analysis (OPLS-DA)

OPLS-DA

Supervised analysis – group membership of data is given and
used to guide analysis
Opmizes separaon between groups rather than maximizing
variaon
OPLS-DA is beer for revealing group structure compared to PCA
Has the potenal to over-opmiscally separate groups
R2 and Q2 are used as metrics to assess predicve ability of the
OPLS-DA model

S-plot

S-plot

Each point represents a single metabolite
S-plots plot the modeled covariance on the x-axis (p) and
correlaon on the y-axis (p(corr))
In the s-plot pictured above, metabolites furthest away from the
origin (with respect to both x- and y-axis) have the highest impact
in separang AKI and non-AKI paents
For example, the metabolite marked by the red box in the s-plot
above indicates a metabolite that is consistently measured at
much higher levels in paents with KDIGO AKI vs. paents
without AKI

Metabolite Idenficaon

Determine metabolites to be idenfied by filtering for p(corr)
values less than -0.4 or greater than 0.4 and using variable
importance in projecon (VIP) value > 1 as a cut-off
VIP values represent the importance of each metabolite in the
OPLS-DA projecon
Idenfy metabolites by querying online metabolomics databases
with the mass/ charge raos (m/z) and fragmentaon paerns of
your unknown metabolites
For example, the metabolite marked by the red box in the S-plot
was idenfied to be tryptophan (pictured above)
Confirm metabolite identy by analyzing samples in parallel with
analycal standards

Figure 4. Sequential overview of the data analysis process.

Note. Encompasses data collection, data processing, and multivariate analysis.

Met ID
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Figure 5. Timeline of progress to date.

Note. Description of progress as of March 2021. This figure was created with BioRender.com.

discovery cohort and higher-level bioinformatics to refine a
targeted predictive algorithm. First and second last or last cisplatin infusions will be analyzed from the validation cohort
samples. This approach allows the validation of within-subject
metabolite variability and determines whether metabolite patterns change after cisplatin exposure. It is likely the analysis
will identify many metabolites implicated in cisplatin AKI,
some of which will be co-linear in their predictive utility.
Therefore, metabolite concentrations will be used to perform
machine learning to limit the number of metabolites to a level
that maximizes prediction and is feasible for implementation.
Based on previous experience, the combination of hyperparameter optimization and feature selection typically results
in biomarkers composed of 5 to 15 metabolites in the final
model.50,71-73 Metabolite levels with stratification of clinical
data from patients (eg, age, cisplatin dose, sex, gender, ethnicity) will be used to create signatures that best predict AKI. The
primary figures of merit for optimization will be area under
the operating characteristic curve (AUROC) and feature-number, with sensitivity, specificity, positive predictive value, and
negative predictive value as secondary metrics. By focusing
on a parsimonious model with the least number of metabolites
given statistically indistinguishable maximal AUC it is

possible to maximize the ease of translation of the model. Both
the final signature and the set of individual univariably significant metabolites will be characterized with MetaboAnalyst to
identify pathways implicated by metabolites that contribute
most to AKI discriminating algorithms and will help identify
injury mechanisms and intervention strategies. The metabolite
model will be explicitly compared with standard AKI prediction with clinical variables alone (net reclassification/integrated discrimination improvement), comparing the difference
in AUCs using the accelerated bootstrap.82-84 Subgroup analyses will be performed (sex, age, cisplatin dose, gender, ethnicity) and cisplatin prediction using the identified metabolites
will be compared between the first vs last or second last cisplatin infusion. Generalization error will be assessed via crossvalidation and the final locked model only will be assessed in
the validation cohort.
Progress. Summary of progress to date shown in Figure 5.

Discussion
ACCENT is a unique study addressing several knowledge
gaps in cisplatin AKI in adults and children. This study has
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several strengths. First, it includes multiple Canadian cancer
treatment centers, with positive implications for generalizability and future knowledge translation. Study protocols
were developed based on experience from the ABLE study,
balancing multicenter feasibility with validity and rigor. Our
consideration of metabolite profile and AKI phenotype
(KDIGO vs electrolyte-based) demonstrates meticulous
attention to disease phenotype allowing for increased accuracy and clinical relevance when identifying biomarkers of
cisplatin AKI. This study will generate a large, valuable biorepository of urine, serum, DNA, and clinical data with the
most detailed and accurate phenotypic description of acute
cisplatin nephrotoxicity available. The robust data analysis
strategy ensures the most reliable candidate metabolites are
identified and our approach in the validation cohort independently validates these findings. The repeated time points
assessment also allows for the validation of within-subject
metabolite variability and determines whether metabolite
patterns change after cisplatin exposure.
A goal is to identify the most predictive metabolites,
which would be amenable to high throughput clinical testing,
like other metabolite panels routinely measured (eg, metabolic diseases, newborn screening). Clinical trials of AKI
mitigation strategies are urgently needed but currently
impractical due to delayed AKI diagnosis. With the discovery of cisplatin AKI metabolites, and by working with industry and biochemistry labs, a rapid and sensitive test can be
developed. An AKI metabolite biomarker panel may be
translated for clinical use to pinpoint the highest risk patients
and trigger conservative AKI mitigation strategies like
avoidance of other nephrotoxic medications, increasing fluid
administration, vigilant monitoring, and active dosage reassessment for future cisplatin infusions. These types of conservative interventions could be tested, via biomarker
(predictive metabolite panel)-driven or guided conservative
process of care intervention trials. In the future, predictive
metabolite panels may be used to risk-stratify patients for
randomization into therapeutic intervention trials.16,18,54,55
We recognize conservative mitigation strategies triggered by
identification of AKI biomarkers pose a potential risk of
undertreated cancer and would need to consider this when
designing future intervention trials. The interdisciplinary
nature of our expert team is a strength by increasing potential
for future research, rapid knowledge dissemination, and
knowledge translation.
Our study has some limitations. Although a relatively large
study, we may be unable to adjust for all clinical variables of
interest when evaluating prediction of AKI. The multicenter
nature, while a strength, also presents opportunities for variability in data collection despite our best efforts. There is risk
of selection bias, as acutely ill patients may not be recruited in
time. We will monitor for this regularly to ensure capture of a
clinically representative population and will modify our
recruitment strategies if needed. The difference in enrollment
period between pediatric and adult patients may impact
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sample stability due to different storage times. This is
unavoidable as cisplatin is used less frequently in the pediatric population and slower recruitment is predicted; however,
the sample storage method should be sufficient to ensure
sample stability for the majority of metabolites. It is possible
we do not find metabolites that predict or aid in early diagnosis of AKI using our planned method. If no new metabolites
are observed during the untargeted LC-MS analysis, we will
use commercially available targeted LC-MS metabolomics
kits. If still unsuccessful, we will use a complementary technique such as nuclear magnetic resonance (NMR). If too
many metabolites are identified, modern shrinkage-based
machine learning can be used to create parsimonious models
that optimize the AUROC while minimizing the number of
features. A similar model is used for newborn screening for
inborn errors of metabolism. This test is performed on every
newborn with 30 to 40 metabolites rapidly screened as an
effective diagnostic test. Similarly, it has been shown that a
panel of 7 metabolites predicts CKD better than SCr alone
(AUC 0.937 vs 0.745), and that classifiers for non-graft rejection kidney injury based on hundreds of metabolites lose very
little performance when only the top 20 metabolites are
used.50,73 This is also relevant when AKI after cisplatin infusion occurs before metabolite biomarkers are obtained. In
these cases, the metabolite panel will not result in earlier AKI
diagnosis but may predict other relevant outcomes like AKI
severity or CKD. This study focuses on acute cisplatin injury,
and not capturing the important potential associations with
CKD; we have mitigated this through the 3-month chart
review, providing valuable hypothesis-generating data to plan
future metabolomics studies to predict long-term kidney
injury. Although our inclusion of a discovery and validation
cohort is a strength, we have chosen to select these cohorts by
random sampling. It may be argued that choosing specific
study sites to provide patients for the discovery cohort, and
other sites, for the validation cohort (ie, select by site) may be
more realistic and generalizable. However, this method may
lack feasibility as metabolomics analyses will only be performed after all participants have been recruited. If we see
that a site-based approach to discovery/validation is feasible,
we may choose this method instead. Any study attempting to
establish new AKI biomarkers faces the issue that the reference standard (ie, SCr rise) is flawed, as described above. Our
work in the ABLE study confirmed that incorporating electrolyte abnormalities into the AKI definition may be important for more accurately phenotyping cisplatin-mediated AKI.
Our study is novel as it attempts to improve our reference
standard by incorporating electrolyte abnormalities into our
reference standard definition.
Future directions may include developing a precision
medicine algorithm where knowledge users can input patient
factors, metabolite concentrations, and pharmacogenetic
variants to determine risk. Given that urine and serum will be
stored, it may be possible to measure protein biomarkers and
compare them against the metabolite measurements already
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planned. Although our study focuses on cisplatin AKI, our
unique methodology may serve as a blueprint for other nephrotoxic therapies like gentamicin and ifosfamide.

Conclusion
To our knowledge, this is the largest study to follow both
children and adults treated with cisplatin. Our study is

unique, innovative, translational, and aims to reimagine the
current model for AKI diagnoses; we will identify novel
metabolomic biomarkers for earlier detection and prediction
of AKI. AKI is associated with CKD and cardiovascularrelated outcomes, which can severely compromise quality of
life. Thus, early detection and prediction may have important
public health implications.

Appendix
Inclusion Criteria
Patients who meet the following criteria are eligible for enrollment as study participants:
Adult

Pediatric

Initiating treatment with cisplatin (≥70 mg/m2)
for head/neck or lung cancer at one of the adult
participating sites; 18 years of age or older

Yes

No

Initiating treatment with cisplatin for any cancer
diagnosis at one of the pediatric participating sites;
greater than 3 months of age; less than 18 years of
age

Consent and/or assent to participate in the study

Exclusion Criteria
Patients who meet any of these criteria are not eligible for enrollment as study participants:
Yes

No

Diagnosis of chronic kidney disease (CKD) at baseline
Previous use of any nephrotoxic drugs included on the provided “Prohibited Nephrotoxic
Medications” list in the 2 weeks prior to the first cycle of cisplatin treatment
Previous use of cisplatin
Previous radiotherapy (total body irradiation or abdominal radiation) in the last month
Previous hematopoietic stem cell transplant
Any chronic or acute health condition that the investigator feels would render the
patient inappropriate for this study, including but not limited to significant uncontrolled
cardiorespiratory, hepatic, infectious, and kidney disease at the discretion of the investigator

Eligibility
Did the participant meet the eligibility requirements for this study?

Yes

No

•• If Yes, informed written consent obtained Yes No
•• If No, do not continue; participant must be excluded.
•• >complete Participant Refusal Log

Additional Consents
Yes

No

Open

Closed

Consent obtained for genetic testing
Consent obtained for future contact
Consent obtained for longitudinal data collection
Consent for future research of leftover blood and urine
samples
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Ethics Approval and Consent to Participate
This study is being conducted in accordance with the World
Medical Association Declaration of Helsinki. Written informed
consent (or assent) will be obtained from all participants, after cancer diagnosis and before cisplatin treatment. Ethics approval was
granted to participating centers in one of three ways: (1) SickKids
provided overarching ethics approval for pediatric centers (REB
Number: 1000071380). Once the application was approved at
SickKids, submissions were made to ethics bodies at other pediatric
sites. (2) We took advantage of the streamlined review process
offered by the Ontario Cancer Research Ethics Board (OCREB) for
our Ontario adult sites (CTO Project ID: 3269). OCREB services
Ontario hospitals/cancer centers conducting oncology trials. Upon
OCREB approval, participating centers may submit their abbreviated center-specific application for expedited approval. (3) The BC
adult site received ethics approval through their center.

Consent for Publication
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7.
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10.

Consent for publication was obtained from all authors.

Availability of Data and Materials
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